Foxo1 Phenotype Annotations - Multigenic Genotypes

Mammalian Phenotype Ontology Annotations
Query Results - Summary

Symbol
Name
ID

Foxo1
forkhead box O1
MGI:1890077

50 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Adipoq^tm1Ish/Adipoq^tm1Ish Foxo1^tm1Rdp/Foxo1^tm1.1Rdp Tg(Col1a1-cre)1Kry/0 involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6J * FVB/N	normal growth/size/body region phenotype	J:199264
	normal homeostasis/metabolism phenotype	J:199264
	normal skeleton phenotype	J:199264
Foxo1^tm1.1Rdp/Foxo1⁺ Igh-J^tm1Cgn/Igh^tm4Cgn Tg(Cr2-cre)3Cgn/0 involves: 129P2/OlaHsd * 129S1/Sv	increased B cell number	J:157297
Foxo1^tm1Flv/Foxo1^tm1Flv Gt(ROSA)26Sor^{tm1(CAG-FOXO1,GFP)Moli}/Gt(ROSA)26Sor⁺ Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6	normal immune system phenotype	J:189962
	normal mortality/aging	J:189962
Foxo1^tm1Flv/Foxo1^tm1Flv Ifng^tm1Ts/Ifng^tm1Ts Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ involves: 129S1/Sv * 129S6/SvEvTac * 129S7/SvEvBrd * 129X1/SvJ	normal immune system phenotype	J:189962
	increased CD4-positive, alpha-beta T cell number	J:189962
	increased CD8-positive, alpha-beta T cell number	J:189962
	normal mortality/aging	J:189962
Foxo1^tm1Flv/Foxo1^tm1Flv Rag1^tm1Mom/Rag1^tm1Mom Tg(CD2-Il7r)1Asin/? Tg(Cd4-cre)1Cwi/? Tg(TcraTcrb)425Cbn/? involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2	decreased T cell number	J:147057
Foxo1^tm1Flv/Foxo1^tm1Flv Rag1^tm1Mom/Rag1^tm1Mom Tg(Cd4-cre)1Cwi/? Tg(TcraTcrb)425Cbn/? involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2	decreased T cell number	J:147057
Foxo1^tm1Mrc/Foxo1^tm1Mrc Myf6^tm1(cre)Mrc/Myf6⁺ Pax3^tm1Mrc/Pax3^tm1Mrc involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	normal neoplasm	J:93444
Foxo1^tm1Rdp/Foxo1^tm1.1Rdp Foxo3^tm1Rdp/Foxo3^tm1.1Rdp Amhr2^tm3(cre)Bhr/Amhr2⁺ involves: 129S6/SvEvTac * 129S7/SvEvBrd	abnormal circulating hormone level	J:232961
	abnormal ovarian follicle morphology	J:232961
	decreased circulating luteinizing hormone level	J:232961
	increased circulating estradiol level	J:232961
	increased granulosa cell tumor incidence	J:232961
	ovary cyst	J:232961
	suppressed circulating follicle stimulating hormone level	J:232961
Foxo1^tm1Rdp/Foxo1^tm1.1Rdp Foxo3^tm1Rdp/Foxo3^tm1.1Rdp Pten^tm1Hwu/Pten^tm1Hwu Tg(CYP19A1-cre)1Jri/0 involves: 129S4/SvJae * 129S6/SvEvTac	abnormal circulating hormone level	J:232961
	decreased circulating luteinizing hormone level	J:232961
	increased granulosa cell tumor incidence	J:232961
	suppressed circulating follicle stimulating hormone level	J:232961
Foxo1^tm1Rdp/Foxo1^tm1.1Rdp Foxo3^tm1Rdp/Foxo3^tm1.1Rdp Tg(CYP19A1-cre)1Jri/0 involves: 129S6/SvEvTac	abnormal circulating hormone level	J:232961
	abnormal granulosa cell morphology	J:232961
	abnormal ovarian follicle morphology	J:232961
	decreased circulating luteinizing hormone level	J:232961
	increased circulating estradiol level	J:232961
	increased granulosa cell tumor incidence	J:232961
	suppressed circulating follicle stimulating hormone level	J:232961
Foxo1^tm1Rdp/Foxo1^tm1.1Rdp Igh-J^tm1Cgn/Igh^tm4Cgn Tg(Cr2-cre)3Cgn/0 involves: 129P2/OlaHsd * 129S1/Sv	absent marginal zone B cells	J:157297
	increased B cell number	J:157297
Foxo1^tm1Rdp/Foxo1^tm1Rdp Foxo3^tm1Rdp/Foxo3^tm1Rdp Foxo4^tm1Rdp/Foxo4^tm1Rdp Tg(Ins2-cre)23Herr/0 involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA/J	abnormal glucose homeostasis	J:215526
	abnormal mitochondrial physiology	J:215526
	abnormal pancreatic beta cell differentiation	J:215526
	abnormal pancreatic beta cell physiology	J:215526
	decreased circulating insulin level	J:215526
	decreased insulin secretion	J:215526
	hyperglycemia	J:215526
	impaired glucose tolerance	J:215526
Foxo1^tm1Rdp/Foxo1^tm1Rdp Foxo3^tm1Rdp/Foxo3^tm1Rdp Foxo4^tm1Rdp/Foxo4^tm1Rdp Tg(Mx1-cre)1Cgn/0 involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N	increased hamartoma incidence	J:118179
	increased hemangioma incidence	J:118179
	increased hemangiosarcoma incidence	J:118179
	increased T cell derived lymphoma incidence	J:118179
	premature death	J:118179
Foxo1^tm1Rdp/Foxo1^tm1Rdp Foxo3^tm1Rdp/Foxo3^tm1Rdp Tg(Mx1-cre)1Cgn/0 involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA * FVB/N	abnormal blood vessel morphology	J:118179
	increased hemangioma incidence	J:118179
	increased hemangiosarcoma incidence	J:118179
	increased hepatic hemangioma incidence	J:118179
	increased tumor incidence	J:118179
	premature death	J:118179
Foxo1^tm1Rdp/Foxo1^tm1Rdp Foxo4^tm1Rdp/Foxo4^tm1Rdp Tg(Mx1-cre)1Cgn/0 involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N	increased hamartoma incidence	J:118179
	increased hemangioma incidence	J:118179
	increased hemangiosarcoma incidence	J:118179
	increased hepatic hemangioma incidence	J:118179
	premature death	J:118179
Foxo1^tm1Rdp/Foxo1^tm1Rdp Irs1^tm1Mfw/Irs1^tm1Mfw Irs2^tm2Mfw/Irs2^tm2Mfw Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA * FVB	abnormal triglyceride level	J:137845
	decreased circulating cholesterol level	J:137845
	decreased circulating free fatty acids level	J:137845
	decreased circulating HDL cholesterol level	J:137845
	decreased circulating triglyceride level	J:137845
	normal homeostasis/metabolism phenotype	J:137845
Foxo1^tm1Whb/Foxo1⁺ Insr^tm1Dac/Insr⁺ involves: 129S4/SvJae * C57BL/6	normal homeostasis/metabolism phenotype	J:79560
Foxo1^tm1Whb/Foxo1⁺ Insr^tm1Dac/Insr^tm1Dac involves: 129S4/SvJae * C57BL/6	decreased circulating glucose level	J:79560
	postnatal lethality	J:79560
Foxo1^tm1Whb/Foxo1⁺ Irs2^tm1Mfw/Irs2^tm1Mfw involves: 129S1/Sv * 129X1/SvJ * C57BL/6	normal endocrine/exocrine gland phenotype	J:80826
	normal homeostasis/metabolism phenotype	J:80826
Foxo1^tm1Whb/Foxo1⁺ Pdpk1^tm1Maka/Pdpk1^tm1Maka Tg(Ins2-cre)23Herr/0 involves: 129S4/SvJae * C57BL/6J * CBA/J	abnormal pancreas physiology	J:109010
	decreased circulating glucose level	J:109010
	increased circulating insulin level	J:109010
	increased pancreatic beta cell number	J:109010
Foxo1^tm2.1Dac/Foxo1^tm2.1Dac Insr^tm1Dac/Insr⁺ involves: 129S4/SvJae * C57BL/6	increased circulating insulin level	J:179687
	insulin resistance	J:179687
Foxo1^tm2.1Dac/Foxo1^tm2.1Dac Lepr^db/Lepr^db B6.Cg-Foxo1^tm2.1Dac Lepr^db	impaired glucose tolerance	J:179687
	increased circulating insulin level	J:179687
Gt(ROSA)26Sor^{tm1(Foxo1)Jnk}/Gt(ROSA)26Sor⁺ Pdpk1^tm1Maka/Pdpk1^tm1Maka Tg(CAG-cat,-lacZ)11Miya/0 Tg(Pomc1-cre)16Lowl/0 involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N	increased body weight	J:162892
Gt(ROSA)26Sor^{tm2(Foxo1)Jnk}/Gt(ROSA)26Sor⁺ Pdpk1^tm1Maka/Pdpk1^tm1Maka Tg(CAG-cat,-lacZ)11Miya/0 Tg(Pomc1-cre)16Lowl/0 involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N	increased body weight	J:162892
	increased food intake	J:162892
	increased total body fat amount	J:162892

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/19/2024 MGI 6.24